Phase 1 N=12 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
Psoriasis
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Ixekizumab (Single Dose) — 6.90 Microgram per milliliter (ug/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation — 26; 5; 4; 0 Participants
Phase 3 N=3,092 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Asthma
Primary: Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26 — 2.050; 2.029; 1.984; 1.953 litre (L) — p=<0.001
N/A N=60 Randomized Controlled Trial to Test an Alzheimer's Family Caregiver Intervention in Vietnam
Family Caregivers
Primary: Zarit Burden Inventory-4 — 2.9; 5.5 score on a scale
Phase 2 N=567 Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
Heavy Uterine Bleeding · Uterine Fibroids
Primary: Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month…
Phase 2 N=117 Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 5.8; 8.1 months — p=0.8956
N/A N=12 A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
Presbyopia
Primary: Visual Acuity — -0.07; -0.05; 0.06; 0.10 LogMAR
Phase 2 N=101 A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
Lymphoma
Primary: Progression-Free Survival (PFS) Time — 36.2; 22.6 months
Phase 2 N=20 Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients
COVID-19
Primary: Number of Participants With Early Viral Clearance — 5; 4; 1; 0 Participants
Phase 2 N=26 A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
Colorectal Cancer · Colorectal Carcinoma · Colorectal Tumor
Primary: Percentage of Participants With Progression-Free Survival (PFS) at 6 Months (PFS Rate) — 26; 23 percentage of participants — p=0.431
N/A N=14 A Dispensing Clinical Trial of Comfilcon A Extended Range Multifocal Lenses
Presbyopia
Primary: Visual Acuity — -0.01; -0.07; -0.15; -0.13 LogMAR
Phase 4 N=401 Topical Antibiotic Prophylaxis for Eyelids
Antibiotic Side Effect · Eyelid; Wound · Eyelid Diseases
Primary: Number of Participants With Surgical Site Infections — 0; 5 Participants — p=0.025
N/A N=23 Efficacy Study of the LARA Wheelchair System for Subacute Stroke Patients
Cerebrovascular Accident
Primary: Fugl-Meyer (FM) Motor Assessment of the Upper Extremity — 28.5; 27.4; 14.2; 7.9 score on a scale
Phase 3 N=606 Lubiprostone in Children With Functional Constipation
Constipation - Functional
Primary: Number of Participants Classified as Overall Responders at Week 12 — 76; 28 Participants — p=0.1609
Phase 3 N=467 Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Primary: Percent Change From Baseline in LDL-C at Week 24 — 1.68; -55.23 percent change — p=< 0.0001